Continue to explore the unexpected impact of systemic uric acid deposition.
|
View in Browser |
|
|
Hello [Prefix] [First Name] [Last Name],
|
Thank you for taking the time to interact with our Systemic Booth at the National Kidney Foundation (NKF) Spring Clinical Meetings. Now you know patients with moderate-to-severe Chronic Kidney Disease (CKD) have a 10-fold increase in gout prevalence.1*
|
Extend the experience virtually for even more insight into uric acid crystal deposition, its often unexpected systemic impact, and a treatment option for your patients with uncontrolled gout.
|
|
|
|
*
|
Data from Krishnan E. Post hoc, cross-sectional analysis of National Health and Nutrition Examination Survey (NHANES) data from 2009-2010 of adults >20 years of age comprehensive patient-focused programs.
|
References: |
1. Krishnan E. PLoS One. 2012;7:e50046 |
|
|
|
|
1 Horizon Way Deerfield, IL 60015
|
|
|
This information is intended for use by U.S. Healthcare Professionals only. This email is intended for the recipient identified above. If you received this email in error, please notify the sender immediately and delete the email from your system.
|
Please DO NOT REPLY to this message. If you would like to contact us, click here or call 866‑479‑6742. If you no longer wish to receive emails, unsubscribe now.
|
The HORIZON logo is a trademark owned by or licensed to Horizon.
|
© 2023 Horizon Therapeutics plc
DA‑UNBR‑US‑01505 04/23
|
www.horizontherapeutics.com
|
|
|
|